Heyma P, Harrison L C
J Clin Invest. 1984 Sep;74(3):1090-7. doi: 10.1172/JCI111476.
The thyrotropin (TSH) receptor is a putative target for autoantibodies in Graves' hyperthyroidism and therefore, should be capable of being identified, isolated, and structurally characterized by immunological means. To this end, four sera from patients with hyperthyroidism, three of which inhibited the binding of 125I-TSH to Triton-solubilized human thyroid membranes, were used to isolate TSH receptors by immunoprecipitation. To account for an effect of TSH binding or receptor occupancy on the ability of Graves' immunoglobulins to precipitate TSH receptors, two approaches were taken: (a) specific 125I-TSH binding activity was measured after solubilized thyroid membranes had been incubated with Graves' sera followed by precipitation with Staphylococcus protein A ("receptor depletion"); (b) TSH binding sites were labeled with 125I-TSH and the complexes were precipitated using Graves' sera and Staphylococcus protein A ("receptor precipitation"). The three sera which inhibited 125I-TSH binding depleted 125I-TSH binding activity between 30-80%. Preformed complexes between Staphylococcus protein A and immunoglobulins in these sera were also able to deplete 125I-TSH binding activity. However, after receptor depletion, the one serum that did not inhibit 125I-TSH binding was associated with a significant increase in 125I-TSH binding. All four sera specifically precipitated 80-100% of receptors identified by prelabeling with 125I-TSH. The dilutions of sera that precipitated 50% of 125I-TSH-receptor complexes ranged from 1:150-1:20. Complexes were partially precipitated by high concentrations of control sera (1:20), but the relative potency of control sera was at least fourfold less than Graves' sera. Immunoprecipitates of 125I-labeled thyroid membranes were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography to reveal Graves'-specific bands of reduced molecular weights of 100-110,000, 80-90,000, and 70-75,000. These bands were similar to those obtained from 125I-labeled thyroid membranes purified by TSH affinity chromatography. Thus, Graves' immunoglobulins: (a) precipitate unoccupied and occupied TSH receptors, (b) in one case, neither inhibit binding nor immunodeplete the unoccupied receptor but immunoprecipitate 125I-TSH-receptor complexes, suggesting that binding of TSH may initiate an interaction between the binding site and a separate immunoreactive molecule, and (c) identify the molecular structure of Graves' autoantigens, putatively, the TSH receptor.
促甲状腺激素(TSH)受体是格雷夫斯氏甲状腺功能亢进症中自身抗体的假定靶点,因此,应该能够通过免疫学方法进行鉴定、分离和结构表征。为此,使用了4例甲状腺功能亢进症患者的血清,其中3例抑制了125I-TSH与Triton溶解的人甲状腺膜的结合,通过免疫沉淀法分离TSH受体。为了说明TSH结合或受体占据对格雷夫斯氏免疫球蛋白沉淀TSH受体能力的影响,采取了两种方法:(a)在溶解的甲状腺膜与格雷夫斯氏血清孵育后,用葡萄球菌蛋白A沉淀(“受体耗竭”)来测量特异性125I-TSH结合活性;(b)用125I-TSH标记TSH结合位点,并用格雷夫斯氏血清和葡萄球菌蛋白A沉淀复合物(“受体沉淀”)。抑制125I-TSH结合的3例血清使125I-TSH结合活性降低了30%-80%。这些血清中葡萄球菌蛋白A与免疫球蛋白预先形成的复合物也能够降低125I-TSH结合活性。然而,在受体耗竭后,1例不抑制125I-TSH结合的血清与125I-TSH结合的显著增加有关。所有4例血清均特异性沉淀了预先用125I-TSH标记鉴定的80%-100%的受体。沉淀50%的125I-TSH-受体复合物的血清稀释度范围为1:150-1:20。高浓度的对照血清(1:20)可部分沉淀复合物,但对照血清的相对效力比格雷夫斯氏血清至少低四倍。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和放射自显影分析125I标记的甲状腺膜的免疫沉淀物,以揭示分子量降低的格雷夫斯氏特异性条带,分别为100000-110000、80000-90000和70000-75000。这些条带与通过TSH亲和层析纯化的125I标记的甲状腺膜获得的条带相似。因此,格雷夫斯氏免疫球蛋白:(a)沉淀未占据和已占据的TSH受体;(b)在1例中,既不抑制结合也不免疫耗竭未占据的受体,但免疫沉淀125I-TSH-受体复合物,这表明TSH的结合可能启动结合位点与另一个免疫反应性分子之间的相互作用;(c)鉴定格雷夫斯氏自身抗原的分子结构,推测为TSH受体。